Breaking: Piper Jaffray Reconfirms $100.0 Target Price On Celgene (NASDAQ:CELG) Shares, Reconfirms Their Original “Hold” Rating

April 17, 2018 - By Robert Sims

Celgene Corporation (NASDAQ:CELG) Logo

Investors sentiment decreased to 0.83 in 2017 Q4. Its down 0.34, from 1.17 in 2017Q3. It dropped, as 156 investors sold Celgene Corporation shares while 478 reduced holdings. 118 funds opened positions while 411 raised stakes. 561.38 million shares or 7.06% less from 603.99 million shares in 2017Q3 were reported.

Wilbanks Smith And Thomas Asset Mngmt Ltd Llc has invested 0.03% of its portfolio in Celgene Corporation (NASDAQ:CELG). Wesbanco Bancorporation has 40,751 shares for 0.29% of their portfolio. Dillon stated it has 52,044 shares or 2.04% of all its holdings. Boston Limited Liability Company holds 0.53% or 234,819 shares in its portfolio. Bridges Counsel holds 1.36% in Celgene Corporation (NASDAQ:CELG) or 23,548 shares. Point72 Asset Management Limited Partnership stated it has 0.09% in Celgene Corporation (NASDAQ:CELG). Intact Inv Management Incorporated accumulated 0.02% or 5,000 shares. Asset Mngmt Inc holds 74,399 shares. 122,053 were accumulated by Highbridge Lc. Moreover, Canada Pension Plan Inv Board has 0.42% invested in Celgene Corporation (NASDAQ:CELG). Dock Street Asset Management Incorporated invested in 0.21% or 5,180 shares. Gsa Cap Llp holds 34,830 shares. 25,073 are owned by Murphy Management. Btg Pactual Asset Management Limited holds 10,557 shares. Caisse De Depot Et Placement Du Quebec owns 68,322 shares.

Since February 8, 2018, it had 1 buy, and 3 insider sales for $3.58 million activity. On Thursday, February 15 the insider KAPLAN GILLA sold $1.77M. $851,093 worth of stock was sold by LOUGHLIN JAMES J on Monday, March 12. Another trade for 13,370 shares valued at $1.26 million was sold by MARIO ERNEST.

Celgene (NASDAQ:CELG) Rating Reaffirmed

Piper Jaffray now has a $100.0 target on the $68.84 billion market cap company or 9.27 % upside potential. In an analyst report shared with investors on Thursday morning, Celgene (NASDAQ:CELG) shares have had their “Hold” Rating reconfirmed by equity research analysts at Piper Jaffray.

Investors sentiment decreased to 0.83 in 2017 Q4. Its down 0.34, from 1.17 in 2017Q3. It dropped, as 156 investors sold Celgene Corporation shares while 478 reduced holdings. 118 funds opened positions while 411 raised stakes. 561.38 million shares or 7.06% less from 603.99 million shares in 2017Q3 were reported.

Wilbanks Smith And Thomas Asset Mngmt Ltd Llc has invested 0.03% of its portfolio in Celgene Corporation (NASDAQ:CELG). Wesbanco Bancorporation has 40,751 shares for 0.29% of their portfolio. Dillon stated it has 52,044 shares or 2.04% of all its holdings. Boston Limited Liability Company holds 0.53% or 234,819 shares in its portfolio. Bridges Counsel holds 1.36% in Celgene Corporation (NASDAQ:CELG) or 23,548 shares. Point72 Asset Management Limited Partnership stated it has 0.09% in Celgene Corporation (NASDAQ:CELG). Intact Inv Management Incorporated accumulated 0.02% or 5,000 shares. Asset Mngmt Inc holds 74,399 shares. 122,053 were accumulated by Highbridge Lc. Moreover, Canada Pension Plan Inv Board has 0.42% invested in Celgene Corporation (NASDAQ:CELG). Dock Street Asset Management Incorporated invested in 0.21% or 5,180 shares. Gsa Cap Llp holds 34,830 shares. 25,073 are owned by Murphy Management. Btg Pactual Asset Management Limited holds 10,557 shares. Caisse De Depot Et Placement Du Quebec owns 68,322 shares.

Since February 8, 2018, it had 1 buy, and 3 insider sales for $3.58 million activity. On Thursday, February 15 the insider KAPLAN GILLA sold $1.77M. $851,093 worth of stock was sold by LOUGHLIN JAMES J on Monday, March 12. Another trade for 13,370 shares valued at $1.26 million was sold by MARIO ERNEST.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 28 analysts covering Celgene (NASDAQ:CELG), 15 have Buy rating, 1 Sell and 12 Hold. Therefore 54% are positive. Celgene has $166.0 highest and $91.0 lowest target. $125.50’s average target is 37.13% above currents $91.52 stock price. Celgene had 59 analyst reports since October 20, 2017 according to SRatingsIntel. The rating was downgraded by JMP Securities to “Hold” on Friday, October 27. Barclays Capital upgraded the stock to “Buy” rating in Tuesday, February 13 report. The firm has “Outperform” rating given on Friday, November 17 by BMO Capital Markets. SunTrust maintained Celgene Corporation (NASDAQ:CELG) on Monday, January 8 with “Buy” rating. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Monday, January 8 by Credit Suisse. The stock of Celgene Corporation (NASDAQ:CELG) has “Outperform” rating given on Wednesday, February 28 by Credit Suisse. The rating was maintained by Stifel Nicolaus on Monday, January 8 with “Buy”. The stock of Celgene Corporation (NASDAQ:CELG) earned “Hold” rating by Citigroup on Friday, October 20. The company was maintained on Wednesday, February 28 by William Blair. The rating was maintained by Guggenheim on Thursday, December 21 with “Buy”.

The stock increased 1.08% or $0.98 during the last trading session, reaching $91.52. About 2.36M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 31.28% since April 17, 2017 and is downtrending. It has underperformed by 42.83% the S&P500.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on April, 26. They expect $1.78 earnings per share, up 16.34 % or $0.25 from last year’s $1.53 per share. CELG’s profit will be $1.34B for 12.85 P/E if the $1.78 EPS becomes a reality. After $1.87 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts -4.81 % negative EPS growth.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $68.84 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 25.14 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: